Metformin has been studied extensively as a potential therapy targeting KLF5 in other cancer types, such as endometrial, prostate and breast cancer, and some metformin cancer studies have sought to target other gene pathways such as the PI3K/Akt/mTOR pathway [44], [45]. This evidence concerns the gene MTOR and breast carcinoma.